HLA-A*03:01 (Monomer) protein (KRAS G12V)
Origine: Humain
Hôte: HEK-293 Cells
Recombinant
> 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
-
- Antigène
- HLA-A*03:01
- Type de proteíne
- Recombinant
- Attributs du protein
- Monomer
- Origine
- Humain
-
Source
- HEK-293 Cells
- Purification/Conjugué
- KRAS G12V
- Fonction
- Human HLA-A*03:01 & B2M & KRAS G12V (VVVGAVGVGK) Monomer Protein
- Séquence
- Gly25-Thr305 (HLA-A*03:01), Ile21-Met119 (B2M) and VVVGAVGVGK peptide
- Specificité
- Uni-Prot: NP_002107.3 (HLA-A*03:01), P61769 (B2M), VVVGAVGVGK
- Attributs du produit
- Recombinant Human HLA-A*03:01 & B2M & KRAS G12V (VVVGAVGVGK) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305(HLA-A*03:01),Ile21-Met119(B2M) and VVVGAVGVGK peptide.
- Pureté
- > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
- Stérilité
- 0.22 μm filtered
- niveau d'endotoxine
- Less than 1EU per μg by the LAL method.
- Biological Activity Comment
- The affinity constant of 0.11 μM as determined in SPR assay (Biacore T200). See testing image for detail.
-
-
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/mL is recommended. Dissolve the lyophilized protein in distilled water.
- Buffer
- Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.
- Stock
- -20 °C,-80 °C
- Stockage commentaire
- -20 to -80°C for 12 months as supplied from date of receipt., -80°C for 3-6 months after reconstitution., 2-8°C for 2-7 days after reconstitution., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Date de péremption
- 12 months
-
- Antigène
- HLA-A*03:01
- Sujet
- Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- Poids moléculaire
- 50.2 kDa. Due to glycosylation, the protein migrates to 55-60 kDa based on Tris-Bis PAGE result.
- NCBI Accession
- NP_002107
-
Vous êtes ici:
